Skip to main content

RNAi / siRNA Deal Benchmarks in Neurology

Median Upfront
$395M
Range: $196M - $597M
Total Deal Value
$3.5B
Range: $2.1B - $4.9B
Royalty Rate
12.9% - 20.6%
Tiered up to 24.6%
Dev Milestones
$1.0B
Range: $627M - $1.4B
Model Your Deal

Market Analysis

RNAi / siRNA therapies in neurology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 rnai / sirna asset in neurology is $395M, with total deal values reaching $3.5B. Development milestones average $1.0B, while regulatory milestones contribute $1.1B.

The neurology rnai / sirna landscape is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for rnai / sirna neurology deals range from 12.9% to 20.6% at the base tier, with tiered escalation reaching 16.9%-24.6% on blockbuster sales. Commercial milestones averaging $961M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a rnai / sirna neurology licensing deal?
Based on our analysis, Phase 2 rnai / sirna licensing deals in neurology average $395M in upfront payments, with a range of $196M to $597M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for rnai / sirna neurology transactions?
The median total deal value for Phase 2 rnai / sirna assets in neurology is $3.5B, ranging from $2.1B to $4.9B. This includes development milestones ($1.0B), regulatory milestones ($1.1B), and commercial milestones ($961M).
What royalty rates are standard for rnai / sirna deals in neurology?
Base royalty rates for rnai / sirna neurology transactions range from 12.9% to 20.6%, with tiered escalations reaching 16.9%-24.6% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in rnai / sirna neurology deals?
RNAi / siRNA neurology deals allocate approximately 89% of total deal value to milestones. Development milestones ($1.0B) make up the largest share, followed by commercial milestones ($961M) and regulatory milestones ($1.1B).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Neurology

View

Monoclonal Antibody in Neurology

View

RNAi / siRNA in Oncology

View

RNAi / siRNA in Cardiovascular

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included